



Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunID NeXT Platform®

April 8, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Apr. 8, 2021--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021.

These abstracts showcase data from [ImmunID NeXT](#), the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

Following are details and links to the scientific posters that will be presented at the online meeting.

Poster Number, Session Category and Session Title	Title & Presenter	Date	Location
399 Clinical Research (Excluding Trials)	Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm Presenter: Rachel Marty Pyke, PhD	April 10, 2021	Online
Biomarkers Predictive of Therapeutic Benefit			
555 Clinical Research (Excluding Trials)	Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy Presenter: Charles Abbott, PhD	April 10, 2021	Online
Liquid Biopsies: Circulating DNA			
1898 Immunology Tumor	Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework Presenter: Rachel Marty Pyke, PhD	April 10, 2021	Online
Antigenicity/Processing and Presentation			
2227 Molecular and Cellular Biology / Genetics	Pan-cancer shedding patterns of tumor circulating cell free DNA Presenter: Fábio Navarro, PhD	April 10, 2021	Online
Genomic Profiling of Tumors			
2241 Molecular and Cellular Biology / Genetics	Profiling tumor-infiltrating immune cells using an augmented transcriptome Presenter: Eric Levy, PhD	April 10, 2021	Online
Genomic Profiling of Tumors			

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency, and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The [Personalis NeXT Platform](#) is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis [Clinical Laboratory](#) is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ([@PersonalisInc](#)).

Forward-Looking Statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, Personalis' business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis' filings with the U.S. Securities and Exchange Commission, including Personalis' most recent reports on Forms 8-K, 10-K and 10-Q, the company's registration statement on Form S-3 filed on December 30, 2020, and the company's prospectus supplement filed on January 27, 2021, and include those listed under the caption "Risk Factors." Personalis disclaims any obligation to update such forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210408005927/en/): <https://www.businesswire.com/news/home/20210408005927/en/>

Investor Relations Contact for Personalis:

Caroline Corner

investors@personalis.com

415-202-5678

Media Contact for Personalis:

Jennifer Havlek

pr@personalis.com

www.personalis.com

650-752-1300

Source: Personalis, Inc.